LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFbeta derived tetrapeptide and a competitive TGF-beta1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-beta1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier[1][2].
Molekulargewicht:
458.60
Reinheit:
99.84
CAS Nummer:
[283609-79-0]
Formel:
C21H42N6O5
Target-Kategorie:
TGF-beta Receptor
Anwendungsbeschreibung:
MCE Product type: Peptides
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
